ストックスクリーナーアプリを入手
1.14
7.32%
-0.09
プレマーケット:
1.12
-0.02
-1.75%
前日終値:
$1.23
開ける：
$1.22
24時間の取引高:
900.66K
Relative Volume:
0.91
時価総額：
$122.12M
収益：
$33.03M
当期純損益:
$-44.63M
株価収益率:
-2.7188
EPS:
-0.4193
ネットキャッシュフロー:
$-36.18M
1週間 パフォーマンス:
-5.79%
1か月 パフォーマンス:
+35.28%
6か月 パフォーマンス:
-22.45%
1年 パフォーマンス:
-46.98%
1日の値動き範囲:
$1.14
$1.23
1週間の範囲:
$1.14
$1.295
52週間の値動き範囲:
$0.6434
$2.38
Maxcyte Inc Stock (MXCT) Company Profile
Compare MXCT vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
1.14 | 131.76M | 33.03M | -44.63M | -36.18M | -0.4193 |
ABT
Abbott Laboratories
|
91.07 | 158.12B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
305.66 | 115.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
81.67 | 105.19B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
48.55 | 72.61B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.96 | 50.35B | 6.30B | 1.07B | 1.09B | 1.8406 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-11 | ダウングレード | BTIG Research | Buy → Neutral |
| 2025-08-07 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2025-07-22 | 開始されました | Stephens | Overweight |
| 2023-11-29 | 開始されました | Craig Hallum | Buy |
| 2021-10-15 | 再開されました | Cowen | Outperform |
| 2021-08-24 | 開始されました | BTIG Research | Buy |
| 2021-08-24 | 開始されました | Cowen | Outperform |
| 2021-08-24 | 開始されました | Stephens | Overweight |
| 2021-08-24 | 開始されました | Stifel | Buy |
| 2021-08-24 | 開始されました | Wedbush | Outperform |
| 2021-08-24 | 開始されました | William Blair | Outperform |
すべてを表示
Maxcyte Inc (MXCT) 最新ニュース
MaxCyte Inc. (MXCT) Posts 3.4% Gain, Testing Resistance at $1.27Entry Point Alerts - newsline.com
MaxCyte (MXCT) Edges Higher on Increased Activity, Tests Key Resistance at $1.27Stop Hunt - The Legal Advocate
MaxCyte Inc. (MXCT) Surges 9.7%: Testing Key Resistance at $1.25Breakout Stock Alerts - The Legal Advocate
MaxCyte Inc. (MXCT) Surges 7.87% as Shares Test Key Resistance LevelMomentum Surge Alerts - The Legal Advocate
MXCT Q1 2026 Earnings: EPS Beat Estimates by 50.98% Despite Negative EarningsDiluted EPS Report - The Legal Advocate
MaxCyte outlines $30M-$32M 2026 revenue outlook as board authorizes $10M share repurchase program - MSN
MaxCyte Inc. (MXCT) Struggles Near Support as Selling Pressure PersistsFree Signal Network - Newser
MaxCyte (MXCT) Q1 2026 Earnings: Narrower Loss Beats Estimates, Stock DeclinesSegment Revenue Breakdown - Newser
MaxCyte Inc stock (US57777K1060): cell-therapy enabler after recent earnings update - AD HOC NEWS
MaxCyte, Inc. (MXCT) reports Q1 loss, tops revenue estimates - MSN
MaxCyte Inc stock (US57777K1060): recent volatility and growth hopes in cell therapy tools - AD HOC NEWS
MaxCyte Q1 earnings call highlights - MSN
What MaxCyte (MXCT)'s -4.59% Decline Means for Investors 2026-05-15Stock Idea Sharing Hub - newser.com
MaxCyte (MXCT) Reports Strong Q1 2026 — Revenue $N/A, EPS BeatsExpert Entry Points - newser.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ibio (IBIO), MaxCyte (MXCT) and Atea Pharmaceuticals (AVIR) - The Globe and Mail
River Global Investors Discloses Investment in MaxCyte with 6.1% Stake - TradingView
River Global Investors builds 6.1% MaxCyte (MXCT) position with 6.53M shares - Stock Titan
Stock Market Today: Dow Jones Futures Fall, S&P 500 Gains As Trump Takes Big Tech Leaders To China—Nvidia, Nextpower, Red Cat In Focus - Sahm
Cisco, Alibaba And 3 Stocks To Watch Heading Into Wednesday - Sahm
MSN Money - MSN
MaxCyte (NASDAQ: MXCT) Q1 2026 revenue dips as expenses fall - Stock Titan
Stifel Maintains MaxCyte(MXCT.US) With Buy Rating, Maintains Target Price $4 - Moomoo
BTIG Maintains MaxCyte(MXCT.US) With Hold Rating - Moomoo
MaxCyte posts $4.8M loss, still lines up $10M stock buyback - Stock Titan
Stock Market Today: Dow Jones Futures Fall, Nasdaq Gains As Trump Takes Big Tech Leaders To China— Nvidia, Nextpower, Red Cat In Focus (UPDATED) - Benzinga
MaxCyte, Inc. (NASDAQ:MXCT) Q1 2026 Earnings Call Transcript - Insider Monkey
Minot Light Capital Partners Q1 2026 Investor Letter - HarianBasis.co
Here’s Why MaxCyte (MXCT) is Becoming a High-Conviction Bet for Investors - Insider Monkey
Earnings Call Summary | MaxCyte(MXCT.US) Q1 2026 Earnings Conference - Moomoo
MaxCyte (MXCT) Earnings Call: Cash-Rich, Growth Delayed - TipRanks
MaxCyte Q1 Earnings Call Highlights - sharewise.com
MaxCyte, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: MaxCyte beats Q1 2026 forecasts with strong revenue By Investing.com - Investing.com South Africa
Earnings call transcript: MaxCyte beats Q1 2026 forecasts with strong revenue - Investing.com Nigeria
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
MaxCyte Reports Q1 2026 Results, Launches Share Buyback - TipRanks
MaxCyte (NASDAQ:MXCT) Q1 2026 Results Beat Estimates, Stock Rises on Buyback - ChartMill
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance - The Manila Times
MaxCyte (NASDAQ: MXCT) Q1 2026 revenue $9.7M as board approves $10M buyback - Stock Titan
Press Release: MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance - Moomoo
Maxcyte Inc (MXCT) 財務データ
収益
当期純利益
現金流量
EPS
Maxcyte Inc (MXCT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Hemrajani Rekha | Director |
Jun 25 '25 |
Sale |
2.09 |
10,684 |
22,378 |
39,893 |
| Swirsky Douglas J | CHIEF FINANCIAL OFFICER |
Aug 13 '25 |
Buy |
1.29 |
50,000 |
64,500 |
161,811 |
| Masoud Maher | President and CEO |
Aug 13 '25 |
Buy |
1.37 |
75,000 |
102,915 |
175,000 |
| Erck Stanley C | Director |
Aug 13 '25 |
Buy |
1.37 |
100,000 |
137,220 |
398,328 |
| DOUGLAS RICHARD | Director |
Aug 13 '25 |
Buy |
1.39 |
80,000 |
111,040 |
230,577 |
| Brooke William W | Director |
Aug 13 '25 |
Buy |
1.29 |
50,000 |
64,500 |
150,879 |
0.74%
1.70%
大文字化:
|
ボリューム (24 時間):